New research suggests that taking semaglutide, the active ingredient in weight-loss drugs like Wegovy and Ozempic, can have a positive impact on heart health in individuals without diabetes. The study, which involved over 17,000 participants, found that semaglutide, a GLP-1 receptor agonist medication, could reduce the risk of cardiovascular events, such as heart attacks and strokes, by 20% in individuals who are overweight, have pre-existing cardiovascular disease, but do not have Type 2 diabetes.
This research, published in the New England Journal of Medicine, is notable as semaglutide was initially prescribed for adults with Type 2 diabetes, a condition affecting a substantial number of individuals in the United States. The findings suggest potential benefits for individuals without diabetes who are seeking to improve their heart health through weight-loss medications containing semaglutide.
Novo Nordisk, the company that funded the most recent study, makes both Wegovy and Ozempic, the two most popular drugs that have semaglutide as the active ingredient. New research suggests
The U.S. Food and Drug Administration (FDA) has granted approval for Ozempic as a treatment for Type 2 diabetes when diet and exercise, combined with other medications, are insufficient in controlling blood sugar levels effectively. While Ozempic is not specifically approved for chronic weight management, it can be prescribed off-label and used safely for individuals who are obese, potentially providing additional benefits beyond glycemic control in the context of diabetes management.